1. Home
  2. GHC vs NAMS Comparison

GHC vs NAMS Comparison

Compare GHC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Graham Holdings Company

GHC

Graham Holdings Company

HOLD

Current Price

$1,163.55

Market Cap

4.8B

Sector

Real Estate

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$32.68

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHC
NAMS
Founded
1877
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.1B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
GHC
NAMS
Price
$1,163.55
$32.68
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$46.75
AVG Volume (30 Days)
15.2K
1.1M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
0.65%
N/A
EPS Growth
N/A
N/A
EPS
66.47
N/A
Revenue
$2,932,099,000.00
N/A
Revenue This Year
$7.73
$17.96
Revenue Next Year
$4.37
$540.65
P/E Ratio
$17.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$882.21
$17.97
52 Week High
$1,224.76
$42.21

Technical Indicators

Market Signals
Indicator
GHC
NAMS
Relative Strength Index (RSI) 59.83 54.05
Support Level $1,028.08 $30.34
Resistance Level $1,197.21 $37.27
Average True Range (ATR) 32.50 1.63
MACD 2.12 0.15
Stochastic Oscillator 70.39 84.05

Price Performance

Historical Comparison
GHC
NAMS

About GHC Graham Holdings Company

Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: